The Board of Directors of Bioalpha wishes to announce that its wholly-owned subsidiary, Bioalpha (HK) Limited (“Bioalpha HK”) had on 28 July 2021 entered into a Memorandum of Agreement with Crawford Laboratory of the Republic of South Sudan (“MOA”) to exclusively undertake the COVID-19 Testing Programme (“Programme”) involving the installation of testing facilities, as well as the provision of testing products and services at border entry points in the country. This will enable the prompt COVID-19 screening of all inbound travellers to South Sudan at these locations.

Please refer attachment for full details of the announcement.

This announcement is dated 28 July 2021.